Loading clinical trials...
Loading clinical trials...
This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come bac...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
TG Therapeutics, Inc.
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
NCT02269592 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, and more
NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
NCT07387471 · Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more
TG Therapeutics Investigational Trial Site
Washington D.C., District of Columbia
TG Therapeutics Investigational Trial Site
Boston, Massachusetts
TG Therapeutics Investigational Trial Site
Hackensack, New Jersey
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions